title: CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma.
abstract: BACKGROUND
  CXCL10, a member of the CXC chemokine family, is known to mediate chemotaxis, apoptosis, angiogenesis, and cell growth. It is also reportedly involved in tumor development and can affect prognosis in several cancers. However, the precise relationship between CXCL10 and the prognosis of patients with esophageal squamous cell carcinoma (ESCC) is not fully understood.
  
  
  METHODS
  We used ESCC tissue microarrays containing samples from 177 patients to test whether the CXCL10 expression status, determined using immunohistochemical analysis, is predictive of prognosis. We also tested whether CXCL10 expression status could serve as a clinically useful marker for evaluating the need for adjuvant chemotherapy after surgery.
  
  
  RESULTS
  We found that high CXCL10 expression in clinical samples was an independent prognostic factor and was predictive of a favorable 5-year overall survival and disease-specific survival (p = 0.0102 and 0.0332, respectively). Additionally, no significant difference was detected between patients in the CXCL10-high group treated with surgery alone and those treated with surgery followed by adjuvant chemotherapy. In the CXCL10-low group, on the other hand, patients treated with surgery followed by adjuvant chemotherapy had better 5-year overall survival than those treated with surgery alone.
  
  
  CONCLUSIONS
  High CXCL10 expression is an independent prognostic factor and has the potential to serve as a clinically useful marker of the need for adjuvant chemotherapy after surgery in patients with advanced thoracic ESCC.
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan. yusuke@doc.med.akita-u.ac.jp.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Sato
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Motoyama
authors.affiliation: Department of Pathology, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nanjo
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Akiyuki
authors.initials: A
authors.lastname: Wakita
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Yoshino
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Sasaki
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Yushi
authors.initials: Y
authors.lastname: Nagaki
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Jiajia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Imai
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Hajime
authors.initials: H
authors.lastname: Saito
authors.affiliation: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Minamiya
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000556:secondary* / Q000628:therapy; D054357:Chemokine CXCL10 / Q000378:metabolism*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D016629:Esophagectomy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D013899:Thoracic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10